RT Journal Article
T1 Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus
A1 Marín López, Alejandro
A1 Calvo Pinilla, Eva
A1 Barriales, Diego
A1 Lorenzo, Gema
A1 Benavente Martínez, Francisco Javier
A1 Brun, Alejandro
A1 Martínez Costas, José Manuel
A1 Ortego, Javier
K1 Bluetongue
K1 Microspheres
K1 MVA
K1 Multiserotype
K1 Vaccine
AB Bluetongue virus (BTV) is the causative agent of bluetongue disease (BT), which affects domestic and wild ruminants. At the present, 27 different serotypes have been documented. Vaccination has been demonstrated as one of the most effective methods to avoid viral dissemination. To overcome the drawbacks associated with the use of inactivated and attenuated vaccines we engineered a new recombinant BTV vaccine candidate based on proteins VP2, VP7, and NS1 of BTV-4 that were incorporated into avian reovirus muNS-Mi microspheres (MS-VP2/VP7/NS1) and recombinant modified vaccinia virus Ankara (rMVA). The combination of these two antigen delivery systems in a heterologous prime-boost vaccination strategy generated significant levels of neutralizing antibodies in IFNAR(−/−) mice. Furthermore, this immunization strategy increased the ratio of IgG2a/IgG1 in sera, indicating an induction of a Th1 response, and elicited a CD8 T cell response. Immunized mice were protected against lethal challenges with the homologous serotype 4 and the heterologous serotype 1 of BTV. All these results support the strategy based on microspheres in combination with rMVAs as a promising multiserotype vaccine candidate against BTV
PB Elsevier
SN 0166-3542
YR 2017
FD 2017-06
LK http://hdl.handle.net/10347/18497
UL http://hdl.handle.net/10347/18497
LA eng
NO Marín-López, A., Calvo-Pinilla, E., Barriales, D., Lorenzo, G., Benavente, J., & Brun, A. et al. (2017). Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus. Antiviral Research, 142, 55-62. doi: 10.1016/j.antiviral.2017.03.010
NO This work was supported by grants from the Spanish Ministerio de Economía y Competitividad (AGL2011-23506, AGL-2014-57430-R and BFU2013-43513-R). Financial support from the Consellería de Cultura, Educación e Ordenación Universitaria (Centro singular de investigación de Galicia accreditation 2016–2019, ED431G/09) and the European Regional Development Fund (ERDF), is also gratefully acknowledged
DS Minerva
RD 28 abr 2026